Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2018, Vol. 23 ›› Issue (3): 296-300.doi: 10.12092/j.issn.1009-2501.2018.03.009

Previous Articles     Next Articles

Expression and clinical significance of matrix metalloproteinase-9 and endothelial cells in patients undergoing cardiac transplantation

DAI Beijun 1, WENG Jianfeng2, HU Zhibin1   

  1. 1 Department of Cardiothoracic Surgery，Zhejiang Provincial People's Hospital，Hangzhou 315000，Zhejiang，China；2 Zhejiang University of Science and Technology，Hangzhou 310023，Zhejiang，China
  • Received:2017-03-27 Revised:2017-08-03 Online:2018-03-26 Published:2018-03-28

PDF (PC)

296

Abstract:

AIM: To investigate the expression and clinical significance of matrix metalloproteinase-9 (MMP-9) and endothelial cell (EPCs) in patients undergoing cardiac transplantation.  METHODS: From January 2012 to January 2016, 120 patients undergoing cardiac transplantation in our hospital were selected as the study group. At the same time, 120 healthy people were selected as the control group according to age and sex matching. The level of MMP-9 in plasma was detected by enzyme linked immunosorbent assay (ELISA). The level of EPCs was detected by Flow cytometry, the difference and correlation between MMP-9 and EPCs in two groups were compared and analyzed. RESULTS:The levels of MMP-9 and EPCs in plasma of patients after heart transplantation were significantly increased, compared with those before transplantation, the difference was statistically significant (P<0.05). The levels of MMP-9 and EPCs before and after heart transplantation in the study group were significantly higher than those in the control group, the difference was statistically significant (P<0.05). The levels of MMP-9 and EPCs in the patients plasma with heart transplantation complication were（128.46±7.32） mg/L and 166.84±14.82, which were significantly higher than those in the normal group（94.25±7.14） mg/L and 134.68±13.68（P< 0.05）. The levels of MMP-9 and EPCs in the patients plasma with heart transplantation death cases were（137.36±8.13） mg/L and 168.24±14.62, which were significantly higher than those in the survival cases (92.85±7.06） mg/L and 98.41±13.24（P <0.05）.The expression of MMP-9 was positively correlated with the expression of EPCs (r=0.686, P=0.000) in patients undergoing heart transplantation. CONCLUSION: The levels of MMP-9 and EPCs in plasma is closely related to early pathologic changes of allograft vasculopathy after heart transplantation; monitoring the dynamic changes of plasma MMP-9 and EPCs of high-risk patients may contribute to observe the early after cardiac allograft vasculopathy tendency after heart transplantation, and timely adjust the treatment plan.

Key words: heart transplantation, matrix metalloproteinase-9, endothelial cell

CLC Number: